Hydroxychloroquine plus CDK4/6 medicine for advanced solid tumors
Part of Cancer clinical trials.
This trial tests whether adding hydroxychloroquine (a medicine that affects a cell recycling process called autophagy) can boost the anti-cancer effect of high-dose CDK4/6 inhibitor treatment in advanced solid tumors. It may help tumors respond better after prior CDK4/6 treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced solid cancer confirmed by pathology (biopsy or cytology), and it has already failed CDK4/6 inhibitor treatment for your situation
- You have at least one measurable tumor spot that can be tracked on scans
- You are 18 or older, with an overall activity level (ECOG) of 0 to 2, and you’re expected to live at least 3 months
- Your recent blood counts and organ function (liver and kidneys) are within required safety ranges based on local lab tests
- You can use reliable birth control if you could become pregnant or if your partner could become pregnant (and you agree to pregnancy testing rules)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two standard hormone therapy pill combinations for advanced breast cancer. One adds a higher dose of palbociclib plus hydroxychloroquine, while the other uses the standard palbociclib dose, to see if the higher dose is more effective.
This trial tests two pills (pazopanib and palbociclib) together for people with advanced solid tumors that have a specific gene change (11q13 amplification) and have stopped responding to other treatments. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a drug called palbociclib for people with advanced liver cancer who have already tried at least two other treatments. The goal is to see if palbociclib can help shrink the cancer or slow its growth.
This trial tests a drug called CPI-613 (devimistat) combined with hydroxychloroquine along with either 5-fluorouracil or gemcitabine chemo. It’s for people with advanced cancers that have stopped responding to standard treatments, aiming to shrink tumors and slow cancer growth.
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
This study tests a combination of two medicines—palbociclib and sasanlimab—in people with advanced clear cell or papillary kidney cancer. It’s mainly designed to check safety (and early signs of how well the treatment may work) in these cancer types.
Hear when a new Inhibition of Autophagy Synergizes Anti-tumor Effect trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.